Background: Sodium-glucose cotransporter-2 inhibitors reduce blood pressure (BP) and renal and cardiovascular events in patients with type 2 diabetes through not fully elucidated mechanisms. Aim of this study was to investigate whether dapagliflozin is able to acutely modify systemic and renal vascular function, as well as putative mechanisms. Methods: Neuro-hormonal and vascular variables, together with 24 h diuresis, urinary sodium, glucose, isoprostanes and free-water clearance were assessed before and after a 2-day treatment with dapagliflozin 10 mg QD in sixteen type 2 diabetic patients; data were compared with those obtained in ten patients treated with hydrochlorothiazide 12.5 mg QD. Brachial artery endothelium-dependent and independ...
BackgroundUntil recently, there are no available preventive measures for macrovascular complications...
Endothelial dysfunction (ED) is a hallmark in type 2 diabetes mellitus (T2DM) that favor both athero...
Background: Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) slow the progression of diabeti...
Abstract Background Sodium-glucose cotransporter-2 inhibitors reduce blood pressure (BP) and renal a...
CONTEXT: Mechanisms mediating the cardiovascular and renal protection exerted by SGLT2 inhibitors ar...
Background and aims: Mechanisms through which SGLT-2 inhibitors achieve cardiovascular and renal pro...
Aims: Sodium-glucose co-transporter 2 (SGLT2) reabsorbs glucose and sodium in the renal proximal tub...
OBJECTIVES: There is a bidirectional relationship between cardiovascular and renal disease. The drug...
Aims: To assess the effect of sodium-glucose cotransporter-2 inhibitor dapagliflozin on natriuresis,...
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve hard renal outcomes in type 2 diabetes. T...
Background: Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) slow the progression of diabeti...
Sodium glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular events and onset and progre...
Dapagliflozin is a selective sodium–glucose cotransporter 2 inhibitor (SGLT2i) indicated for the tre...
In patients with diabetes, glycemic improvement by sodium-glucose cotransporter-2 inhibition depends...
Sodium glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular events and onset and progre...
BackgroundUntil recently, there are no available preventive measures for macrovascular complications...
Endothelial dysfunction (ED) is a hallmark in type 2 diabetes mellitus (T2DM) that favor both athero...
Background: Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) slow the progression of diabeti...
Abstract Background Sodium-glucose cotransporter-2 inhibitors reduce blood pressure (BP) and renal a...
CONTEXT: Mechanisms mediating the cardiovascular and renal protection exerted by SGLT2 inhibitors ar...
Background and aims: Mechanisms through which SGLT-2 inhibitors achieve cardiovascular and renal pro...
Aims: Sodium-glucose co-transporter 2 (SGLT2) reabsorbs glucose and sodium in the renal proximal tub...
OBJECTIVES: There is a bidirectional relationship between cardiovascular and renal disease. The drug...
Aims: To assess the effect of sodium-glucose cotransporter-2 inhibitor dapagliflozin on natriuresis,...
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve hard renal outcomes in type 2 diabetes. T...
Background: Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) slow the progression of diabeti...
Sodium glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular events and onset and progre...
Dapagliflozin is a selective sodium–glucose cotransporter 2 inhibitor (SGLT2i) indicated for the tre...
In patients with diabetes, glycemic improvement by sodium-glucose cotransporter-2 inhibition depends...
Sodium glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular events and onset and progre...
BackgroundUntil recently, there are no available preventive measures for macrovascular complications...
Endothelial dysfunction (ED) is a hallmark in type 2 diabetes mellitus (T2DM) that favor both athero...
Background: Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) slow the progression of diabeti...